Skip to main content
. 2019 Jan 11;10(4):494–510. doi: 10.18632/oncotarget.26563

Figure 6. Bliss Independence analysis to evaluate synergistic activity between ABT-263 (navitoclax) and A-1210477.

Figure 6

Cell viability curves and Bliss Independence analysis scores after treatment with ABT-263 (navitoclax) and A-1210477 across varying doses in PCI15B (A), Detroit 562 (B), MDA686LN (C), and HN30 (D).